Products for Research Use Only
RegisterLogin

YN14

CAT: 0804-HY-155356-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-155356-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
YN14 is a KRASG12C proteolysis targeting chimera (PROTAC) . YN14 is highly potent and selective KRASG12C degrader and induces a stable KRASG12C: YN14: VHL ternary complex with low binding free energy (ΔG) . YN14 has antiproliferative effects and significantly inhibits KRASG12C-mutant cancer cell growth. YN14 leads to tumor regression with tumor growth inhibition (TGI%) rates more than 100 % in the MIA PaCa-2 xenograft model.
UNSPSC
12352005
Target
PROTACs; Ras
Type
Reference compound
Related Pathways
GPCR/G Protein; MAPK/ERK Pathway; PROTAC
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/yn14.html
Purity
99.0800
Solubility
10 mM in DMSO
Smiles
O=C(C=C)N1C[C@H](C)N(C2=NC(N(C3=C(C)C=CN=C3C(C)C)C4=NC(C5=C(OCC6CCN(CCCC(N[C@@H](C(C)(C)C)C(N7[C@H](C(NCC8=CC=C(C9=C(C)N=CS9)C=C8)=O)C[C@@H](O)C7)=O)=O)CC6)C=CC=C5F)=C(F)C=C42)=O)CC1
Molecular Formula
C62H75F2N11O7S
Molecular Weight
1156.39
References & Citations
[1]Ning Yang, et al. Discovery of highly potent and selective KRASG12Cdegraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation. Eur J Med Chem. 2023 Dec 5:261:115857.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Related Products

CatalogName
HY-N12934Z13, YN11-16:OH
HY-P99127-01Anti-Mouse CD54 Antibody (YN1/1.7.4)

Alternative Products

CatalogName
T80750-01YN14
GTR19259013-01YN14-H
T212210-01YN14 (mixture of diastereomers)

Popular Products